MTOR and neoplasm: Additionally, considering the potential anti‐tumor effects of Rapamycin (mTOR inhibitor), we evaluated the combinational inhibitory effects of CFI‐402257 and Rapamycin on the proliferation of TCL cells, and found that the combined treatment with Rapamycin enhanced anti‐TCL effect of CFI‐402257 (Figure 5F).